#ECTRIMS2021 – Real-world Data Support Mavenclad Benefits in Relapsing MS

#ECTRIMS2021 – Real-world Data Support Mavenclad Benefits in Relapsing MS

309254

#ECTRIMS2021 – Real-world Data Support Mavenclad Benefits in Relapsing MS

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Mavenclad (cladribine) improves life quality for people with relapsing multiple sclerosis starting in the first year of treatment, and continues to slow disability progression a decade after its last treatment course, real-world data show. These findings…

You must be logged in to read/download the full post.